Pfizer News and Research RSS Feed - Pfizer News and Research

Global depression drugs market estimated to grow at 2.49% CAGR by 2018

Global depression drugs market estimated to grow at 2.49% CAGR by 2018

Research and Markets has announced the addition of the "Global Depression Drugs Market 2014-2018" report to their offering. [More]
Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis. [More]

Pfizer to highlight Blue Button initiative at DIA 2014 Annual Meeting in San Diego

Craig Lipset, head of clinical innovation at Pfizer Inc., will join advocates of patient data accessibility to highlight the Blue Button initiative at the DIA 2014 50th Annual Meeting in San Diego. [More]
Global hemophilia market to grow at 6.07% CAGR by 2018

Global hemophilia market to grow at 6.07% CAGR by 2018

Research and Markets has announced the addition of the "Global Hemophilia Market 2014-2018" report to their offering. [More]
Cancer Research partners with AstraZeneca and Pfizer to create clinical trial for advanced lung cancer

Cancer Research partners with AstraZeneca and Pfizer to create clinical trial for advanced lung cancer

CANCER RESEARCH UK is partnering with pharmaceutical companies AstraZeneca and Pfizer to create a pioneering clinical trial for patients with advanced lung cancer - marking a new era of research into personalised medicines to treat cancer. [More]
Researchers create clinical trial for patients with advanced lung cancer

Researchers create clinical trial for patients with advanced lung cancer

Cancer Research UK is partnering with pharmaceutical companies AstraZeneca and Pfizer to create a pioneering clinical trial for patients with advanced lung cancer - marking a new era of research into personalised medicines to treat cancer. [More]

Research report on global dermatophytic onychomycosis therapeutics market

Research and Markets has announced the addition of the "Global Dermatophytic Onychomycosis Therapeutics Market Report" report to their offering. [More]

PDS launches new data sharing platform to improve lives of cancer patients

Project Data Sphere, LLC (PDS), an independent not-for-profit initiative of the CEO Roundtable on Cancer's Life Sciences Consortium (LSC), announced today the launch of a new data sharing platform (www.ProjectDataSphere.org), with the goal of advancing research to improve the lives of cancer patients and their families around the world. [More]
Kidney disease patients with poor quality of life at increased risk of developing heart problems

Kidney disease patients with poor quality of life at increased risk of developing heart problems

Kidney disease patients with poor quality of life are at increased risk of experiencing progression of their disease and of developing heart problems, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. The findings suggest that quality of life measurements may have important prognostic value in these individuals. [More]
Competitive Intelligence Report on biosimilar and biosuperior therapeutic antibodies

Competitive Intelligence Report on biosimilar and biosuperior therapeutic antibodies

Research and Markets has announced the addition of the "Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies" report to their offering. [More]

Detailed analysis of ADC technologies, business activities and opportunities

Research and Markets has announced the addition of the "Antibody-Drug Conjugates 2014 - a Business, Technology & Pipeline Analysis" report to their offering. [More]
Researcher honored with Pfizer/ACMG Foundation Translational Genomic Scholars Fellowship Award at ACMG

Researcher honored with Pfizer/ACMG Foundation Translational Genomic Scholars Fellowship Award at ACMG

Xiangling Wang, MD, PhD of Mayo Clinic in Rochester, MN was honored as the 2014-2015 recipient of the Pfizer/ACMG Foundation Clinical Genetics Combined Residency for Translational Genomic Scholars Fellowship Award at the ACMG 2014 Annual Clinical Genetics Meeting in Nashville, TN. [More]
EMD Serono collaborates with Pfizer and Broad Institute

EMD Serono collaborates with Pfizer and Broad Institute

EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, today announced they have signed a research agreement with Pfizer Inc. and the Broad Institute in Cambridge, Massachusetts, U.S. The collaboration is focused on the genomic profiling of Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) patients. [More]
Halozyme meets primary endpoint in Hylenex CONSISTENT 1 trial

Halozyme meets primary endpoint in Hylenex CONSISTENT 1 trial

Halozyme Therapeutics, Inc. today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex® recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion (CSII) in comparison to no pre-treatment. [More]

Pfizer issues statement on FDA approval of non-prescription drug, Nexium 24HR

Today the U.S. Food and Drug Administration (FDA) approved over-the-counter Nexium® 24HR (esomeprazole 20mg) marking a key step towards providing those who suffer from frequent heartburn broader access to a brand doctors and patients have trusted for years. [More]
New -7 million centre to lead research in manufacturing advanced chemical products

New -7 million centre to lead research in manufacturing advanced chemical products

A new -7 million centre at the University of Leeds will lead UK research in manufacturing advanced chemical products. The Centre for Doctoral Training (CDT) in Complex Particulate Products and Processes will fund 50 new research students in a field that has been targeted by the Government as a key growth area for the UK economy. [More]

MD Anderson's Jim Allison honored with 2014 Canada Gairdner International Award

A Canadian institution that annually recognizes seminal medical discoveries selected cancer immunotherapy leader Jim Allison, Ph.D., chair and professor of Immunology at The University of Texas MD Anderson Cancer Center, for one of its 2014 Canada Gairdner International Awards. [More]
EC approves Roche's SC formulation of MabThera for common forms of non-Hodgkin lymphoma

EC approves Roche's SC formulation of MabThera for common forms of non-Hodgkin lymphoma

Halozyme Therapeutics, Inc. announced today that the European Commission has approved Roche's new subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. [More]

pSivida resubmits New Drug Application for ILUVIEN

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been resubmitted to the U.S. Food and Drug Administration (FDA). [More]
Dr. Reddy's Laboratories launches Amlodipine Besylate and Atorvastatin Calcium Tablets

Dr. Reddy's Laboratories launches Amlodipine Besylate and Atorvastatin Calcium Tablets

Dr. Reddy's Laboratories announced today that it has launched Amlodipine Besylate and Atorvastatin Calcium Tablets 2.5/10mg, 2.5/20mg, 2.5/40mg, 5/10mg, 5/20mg, 5/40mg, 5/80mg, 10/10mg, 10/20mg, 10/40mg and 10/80 mg a therapeutic equivalent generic version of CADUET (amlodipine Besylate and atorvastatin calcium) tablets, in the US market on March 26, 2014, following the approval by the United States Food & Drug Administration. [More]